

- Chest radiography, **308e-1**  
 in alveolar processes, 308e-10f  
 in anthrax, 261e-3, 261e-4f  
 in ARDS, 1737f  
 in asthma, 1675  
 in bronchiectasis, 308e-11f  
 in chest pain evaluation, 101  
 in dyspnea, 47e-4  
 in hemoptysis, 246  
 in hypersensitivity pneumonitis, 1682  
 in interstitial lung disease, 308e-7-9f, 1710  
 in Legionnaires' disease, 1016, 1017f  
 in lung cancer, 308e-15f  
 in lung cancer screening, 509-510, 510t  
 in lymphadenopathy, 409  
 normal, 308e-1f  
 in parenchymal loss, 308e-5-6f  
 in pleural effusion, 308e-14f  
 in pneumococcal pneumonia, 951f  
 in pneumothorax, 308e-13f  
 in pulmonary edema, 47e-5  
 in pulmonary hypertension, 308e-18f, 1656, 1658f  
 in respiratory disease evaluation, 1663, 1664f, 1665f  
 in volume loss, 308e-3-4
- Chest tightness, 47e-1, 47e-1t
- Chest tube drainage, for pleural effusion, 474
- Chest wall  
 abnormality of, ventilatory restriction due to, 306e-5, 1721  
 compliance of, 306e-1-2, 1733  
 disorders of, 47e-2  
 pressure-volume curves of, 306e-1f  
 tenderness in, 100  
 trauma to, 51e-2
- Chewing tobacco, 476
- Cheyne-Stokes respiration  
 in central sleep apnea, 1726f, 1727  
 in coma, 1775  
 in heart failure, 1504  
 in terminally ill patient, 68, 69t
- CHF (congestive heart failure). *See* Heart failure (HF)
- Chiari malformation, 2658, 2658f
- Chiasmal tumor, 206-207
- Chiasmata, 428
- Chickenpox. *See* Varicella
- Chief cells, 1914
- Chiggers, 2745
- Chigoe flea, 2750
- Chikungunya virus infection  
 climate change and, 151e-4-5  
 clinical features of, 130t, 134, 837, 1313  
 epidemiology of, 130t, 134, 151e-4-5, 802, 894, 1313  
 reservoirs and vectors of, 1306t, 1313  
 treatment of, 1313
- Chilblain (pernio), 478e-4, 1648f, **1649**
- Child abuse, 17e-1, 167e-2, 2722
- Child-Pugh classification, of cirrhosis, 1994-1995, 1995t
- Children  
 atopic dermatitis in, 344  
 ECG in, 269e-14f  
 fever treatment in, 126  
 GH deficiency in, 2257-2258  
 Graves' disease in, 2296  
 HIV infection in, 1226, 1226f  
 liver transplantation in, 2068, 2068t  
 malaria in, 1374  
 mortality rates in, 9, 13e-3f, 13e-6f, 93e-1-2  
 rheumatic fever in, 2149  
 seizures in, 2545-2546, 2546t  
 smoking in, 475
- Child-Turcotte-Pugh (CTP) score, 2069
- Chile, 13e-6
- Chilean Rose tarantula, 2748
- Chimeric antigen receptor (CAR), 91e-4
- Chimpanzee, as HIV reservoir, 1219
- China, 13e-7, 13e-7f
- Chinese herbal nephropathy, 577, 1804, 1856t, 1861
- Chios virus, 1309t
- CHIPS, 956
- Chironex fleckeri* sting, 76e-11f
- Chiropractic, 14e-1t, 14e-2-3
- Chlamydia* spp., 1165-1166, 1166f
- Chlamydia psittaci*, 1172-1173
- Chlamydia trachomatis*, 1165-1166
- Chlamydia trachomatis* infections  
 anorectal, 881  
 genitourinary, **1167**  
 diagnosis of, 150e-6, 771, 1170-1171, 1170t  
 epidemiology of, 869, 1167  
 epididymitis, 872, 1168  
 incidence of, 869  
 lymphogranuloma venereum. *See* Lymphogranuloma venereum  
 mucopurulent cervicitis, 1168-1169  
 partner-delivered therapy for, 1171  
 pathogenesis of, 1166-1167  
 proctitis, 1168, 1169  
 screening for, 29t, 882, 1172  
 spectrum of, 1167  
 treatment of, 871, 872t, 1171  
 urethral syndrome in women, 1169  
 urethritis, 870, 872, 1167-1168  
 in immunocompromised patients, 489, 489t  
 in neonates, 1169, 1170t, 1171  
 pelvic inflammatory disease. *See* Pelvic inflammatory disease (PID)  
 perihepatitis, 1169  
 in pregnancy, 1169  
 prevention of, 1171-1172  
 reactive arthritis, 1168  
 trachoma, 199, **1172**
- Chlamydophila pneumoniae* infections, **1173**
- Chloral hydrate, 473e-11t
- Chlorambucil, 103e-8, 103e-9t
- Chloramphenicol  
 action of, 931t, 932  
 adverse effects of, 938t, 945  
 aplastic anemia, 664t  
 bone marrow failure, 678  
 neutropenia, 417  
 optic neuropathy, 203  
 pure red cell aplasia, 668t  
 for anaerobic bacterial infections, 1101, 1102  
 for *Campylobacter* infections, 1061  
 for Carrión's disease, 1081t  
 for donovanosis, 198e-2  
 drug interactions of, 945  
 for enteric fever, 1052t  
 indications for, 941t, 944-945  
 for meningitis, 1011  
 for meningococcal infections, 1000  
 for plague, 261e-5, 261e-5t, 1074t  
 in pregnancy and lactation, 937t  
 for relapsing fever, 1148f  
 resistance to, 931t, 934  
 for scrub typhus, 1159  
 therapeutic monitoring of, 2764t  
 for tick-borne spotted fevers, 1157  
 for tularemia, 261e-5t, 261e-7  
 for Whipple's disease, 1945
- Chlordiazepoxide  
 for alcohol withdrawal, 2727, 2728  
 for anxiety disorders, 2711t  
 overdose/poisoning with, 473e-10t, 2764t  
 pharmacology of, 2711t  
 therapeutic monitoring of, 2764t
- Chlorhexidine bath, 918
- Chlorhexidine mouthwash, 216
- Chloride  
 parenteral requirement for, 98e-5t  
 recommended intake of, 95e-2t  
 reference values for, 2758t  
 renal transport of, 332e-3f, 332e-7-8
- Chloride channel activators. *See* Lubiprostone
- Chloride channel disorders, of muscle, 462e-18
- Chloridorrhea, congenital, 254
- Chlorine, as chemical terrorism agent, 262e-1
- Chlornaphazine, 575
- 2-Chlorodeoxyadenosine, 103e-10t, 103e-14
- Chloroma, cutaneous (granulocytic sarcoma), 366
- Chloroquine  
 action of, 246e-8  
 adverse effects of  
 bone marrow failure, 664t  
 common, 1380t  
 cutaneous, 353, 381  
 hair discoloration, 380  
 myopathy, 462e-20, 462e-20t, 2199  
 neuropathy, 2686, 2687t  
 occasional, 246e-1t, 1383  
 ocular, 206, 1383  
 rare, 246e-1t, 246e-8, 1380t  
 drug interactions of, 246e-1t  
 genetic variations in response to, 39t  
 for hypercalcemia, 314  
 for malaria, 1378t, 1379, 1380t  
 for malaria prophylaxis, 796t, 1383, 1383t  
 overdose/poisoning with, 473e-13t  
 pharmacology of, 246e-8, 1380t  
 for porphyria cutanea tarda, 390, 2530  
 resistance to, 1370f, 1379  
 for SLE, 2132  
 for Whipple's disease, 1094
- Chlorothiazide, 462e-18
- Chlorproguanil, 246e-4t
- Chlorpromazine  
 adverse effects of, 2721, 2722t  
 cholestatic hepatitis, 284  
 chronic cholestasis, 284  
 cutaneous, 379  
 lupus syndrome, 2218t  
 photoallergy, 389t  
 secondary parkinsonism, 2611  
 for delirium, 64t, 65  
 drug interactions of, 42  
 for dyspnea, 62  
 for medication-overuse headache, 109  
 for migraine, 2592, 2592t  
 overdose/poisoning with, 473e-8t, 473e-9t  
 parenteral, 2592, 2592t  
 for schizophrenia, 2721, 2722t
- Chlorpropamide, 82, 727t, 2413
- Chlorthalidone, 1624t
- Choclo virus, 1307t
- Choking/pulmonary-damaging agents, 262e-1t, 262e-2t
- Cholangiocarcinoma, **552**  
 clinical features of, 552  
 diagnosis of, 552-553  
 etiology of, 552  
 extrahepatic cholestasis in, 285  
 in sclerosing cholangitis, 2086  
 sites of origin of, 552  
 treatment of, 553, 1885f
- Cholangiopancreatography  
 endoscopic. *See* Endoscopic retrograde cholangiopancreatography (ERCP)  
 magnetic resonance. *See* Magnetic resonance cholangiopancreatography (MRCP)
- Cholangitis  
 abdominal pain in, 106t  
 ascending, 1892-1893  
 in choledocholithiasis, 1884f, 2083  
 immunoglobulin G4-associated, 2085, 2099  
 primary sclerosing. *See* Primary sclerosing cholangitis (PSC)  
 in transplant recipient, 924t, 927
- Cholecystectomy  
 complications of, 2080, 2082-2083  
 for hyperplastic cholecystoses, 2083  
 indications for, 2080  
 with splenectomy, in hereditary spherocytosis, 652
- Cholecystitis, **2080**  
 acalculous, 2081  
 acute, 2080-2081  
 chronic, 2081  
 clinical features of, 2080  
 abdominal pain, 106, 106t, 2080  
 chest pain, 98  
 nausea and vomiting, 258, 2080  
 complications of, 2081-2082  
 diagnosis of, 107, 2081  
 emphysematous, 2081